Is Your Paper Ready for Circulation? The AHA's Clinical Cardiology Standard

One of the most common mistakes in cardiovascular publishing is submitting to the wrong AHA journal. The AHA runs over a dozen specialty titles, and the editorial teams actively redirect manuscripts they think landed in the wrong place. Understanding this family matters because a paper that's wrong for Circulation might be perfect for one of its siblings.

The editors at Circulation won't just reject a misplaced manuscript. They'll sometimes suggest which AHA journal would be a better fit. But don't rely on this kindness. Submitting to the wrong journal wastes weeks of editorial processing time, and the redirect isn't automatic. You'll need to reformat, resubmit, and start the review clock from scratch.

If your paper is fundamentally about a heart failure intervention, submit to Circulation: Heart Failure first. If it's about arrhythmia management, start with Circulation: Arrhythmia and Electrophysiology. Reserve Circulation itself for findings that cut across subspecialties or that would change how all cardiologists practice, not just electrophysiologists or heart failure specialists.

This is where Circulation differs from every other top medical journal, and where many submissions fail. Every original research article must include two structured boxes:

"What Is New?" requires 2-3 bullet points summarizing the novel findings. These aren't abstract conclusions restated in bullets. They're supposed to communicate exactly what this paper adds to existing knowledge that wasn't known before.

"What Are the Clinical Implications?" requires 2-3 bullet points explaining how these findings could affect patient care, clinical decision-making, or guideline development.

Both boxes together can't exceed 100 words. That's a tight constraint, and it's intentional. The editors use these boxes as a first-pass triage tool. If your clinical implications are vague ("these findings may have important implications for cardiovascular risk assessment"), you've told the editor nothing. You've essentially admitted your paper doesn't have a clear clinical message.

Strong clinical implications bullets look like this: "Patients with elevated troponin-T and normal coronary arteries should be evaluated for microvascular disease, which was present in 64% of our cohort." That's specific. A cardiologist reads it and knows what to do differently.

Weak ones look like this: "Our findings suggest that additional biomarkers may improve risk prediction." That's every biomarker paper ever written. The editor has already moved on.

Don't treat these boxes as an afterthought. Write them first. If you can't produce two concrete clinical implications bullets in under 50 words, your paper may not be ready for Circulation.

Circulation and the European Heart Journal (EHJ) are the two highest-impact general cardiology journals in the world. They compete for the same papers, but they aren't interchangeable. The editorial cultures, readership bases, and publication priorities differ in ways that should influence where you submit.

Circulation's editors think in terms of AHA/ACC guideline relevance. If your clinical trial could change an AHA practice guideline, Circulation is the natural home. EHJ's editors think in terms of ESC guidelines. A European multicenter trial evaluating ESC-recommended therapies fits EHJ better than Circulation, even if the science is identical.

There's also a philosophical difference. Circulation tends to prioritize large randomized controlled trials and population-based studies with hard clinical endpoints (mortality, MACE, hospitalization). EHJ publishes those too, but it's somewhat more receptive to mechanistic clinical studies, imaging-based research, and translational work that connects pathophysiology to clinical phenotypes.

Geography matters more than researchers admit. A study conducted entirely in US hospitals, using US patient populations, and comparing treatments against AHA-recommended standards, is going to resonate more with Circulation's editors. The reverse applies to EHJ.

If your study has global relevance and could influence both AHA and ESC guidelines, you'll need to decide based on secondary factors: speed (Circulation is slightly faster), formatting requirements (do you prefer structured boxes or graphical abstracts?), and which guideline committee you want paying attention.

More than 70% of submissions never reach external review. Circulation's editors are making fast decisions, often within 1-2 weeks. Here's what gets a paper rejected before any reviewer sees it:

No clear clinical message. The single most common reason. Your paper might be well-designed and well-executed, but if the editors can't identify a direct clinical implication within the first few minutes of reading, it's going back.

Basic science without clinical connection. Elegant mechanistic work on cardiomyocyte biology, vascular remodeling, or cardiac electrophysiology will get redirected to Circulation Research. This happens even when the findings are novel and impactful, because Circulation's editorial mandate is clinical practice.

Underpowered clinical studies. Small, single-center studies with surrogate endpoints instead of hard clinical outcomes. If your heart failure trial enrolled 80 patients and measured only BNP levels rather than hospitalizations or mortality, Circulation isn't going to bite.

Incremental findings. Showing that a known risk factor is also a risk factor in a slightly different population doesn't clear the bar. The finding needs to change practice, not confirm existing practice.

Poor "What Is New?" boxes. As discussed above, vague or generic clinical implications bullets signal that the paper doesn't have a clear clinical takeaway. Editors notice.

Missing critical elements. Forgetting the structured boxes, submitting without a cover letter, or ignoring the word limits. These are fixable problems, but they create a bad first impression during triage.

Regional studies with limited generalizability. A single-center study from one hospital analyzing local registry data rarely makes it into Circulation unless the sample size is massive or the clinical question is unique enough to override external validity concerns.

Circulation's editorial team processes a high volume of submissions. When your paper arrives, here's what actually happens.

The managing editor assigns it to a handling editor based on topic. That editor reads your title, abstract, and the "What Is New?" / "What Are the Clinical Implications?" boxes. This takes about five minutes. In those five minutes, the editor is answering one question: is this paper potentially practice-changing?

If the answer is yes, the paper moves to a brief editorial discussion. Two or three editors will weigh in, and if they agree, the paper goes out for peer review. If the answer is no, or if there's ambiguity, the paper gets desk-rejected.

This is why those structured boxes matter so much. They're not a formality. They're the first thing an editor reads after the abstract, and they're designed to force you to articulate your clinical contribution in the most compressed way possible. An editor processing dozens of submissions per week is going to use those boxes as a sorting mechanism.

The speed of this process explains Circulation's fast turnaround. Decisions in fewer than 21 days means the editorial team isn't deliberating for weeks. They're making rapid assessments based on clear criteria: clinical relevance, study design, sample size, and endpoint selection.

Before you submit to Circulation, answer these honestly:

1. Can a practicing cardiologist change their clinical behavior based on your findings? Not theoretically, not eventually. Right now.

1. Are your primary endpoints hard clinical outcomes? Mortality, MACE, heart failure hospitalization, and stroke are strong. Surrogate biomarker endpoints are weaker unless they're already validated.

1. Is your study multicenter? Single-center studies face a steep disadvantage at Circulation unless the sample size compensates or the clinical question can only be answered at a specialized center.

1. Can you write two concrete "Clinical Implications" bullets in under 50 words? If you can't, your paper's clinical message probably isn't clear enough.

1. Does your paper belong in Circulation, or in one of the AHA subspecialty journals? Be honest. A paper about cardiac resynchronization therapy outcomes belongs in Circulation: Heart Failure or Circulation: Arrhythmia and Electrophysiology, not the flagship.

1. Is there basic science without a clinical anchor? If you've got three figures of molecular data and one figure of clinical data, Circulation Research is probably the better home.

1. Would your finding affect AHA/ACC guidelines? Papers that can plausibly influence US cardiology guidelines have the strongest alignment with Circulation's editorial priorities.

1. Is your sample size adequate? Look at recent Circulation papers in your area. What sample sizes are they reporting? If yours is an order of magnitude smaller, you'll need an exceptionally strong clinical question to compensate.

1. Have you checked your structured boxes against published examples? Read the "What Is New?" and "What Are the Clinical Implications?" boxes from five recent Circulation papers in your subspecialty. Match that level of specificity.

1. Have you run your manuscript through a pre-submission check? Before investing time in Circulation's specific formatting requirements, a free manuscript assessment can identify structural issues, scope misalignment, and clinical messaging gaps that trigger desk rejection.

These aren't generic submission mistakes. They're patterns that specifically get papers rejected from Circulation.

The "translational" paper that's really basic science. You've done some elegant work on cardiac fibrosis pathways and added a small clinical cohort to make it look translational. The editors can tell. If the basic science is the real contribution and the clinical data is a thin layer on top, submit to Circulation Research instead.

The registry study that confirms the obvious. Using a large database to show that patients with more comorbidities have worse outcomes isn't going to excite Circulation's editors. Registry studies need to reveal unexpected patterns, validate novel risk scores, or identify subgroups where current guidelines may be wrong.

The imaging study that belongs in a subspecialty journal. Showing that a new imaging technique can detect something isn't enough. You need to demonstrate that detecting it changes outcomes. Otherwise, Circulation: Cardiovascular Imaging is the right target.

The genetic association study without functional validation. Identifying a genetic variant associated with cardiovascular risk is interesting, but Circulation wants the clinical utility. Can it improve risk prediction beyond established models? Does it identify patients who benefit from specific therapies?

The international trial reported as if it's US-focused. Circulation has global readership, but its editorial lens is US cardiology practice. If your trial was conducted in settings with different treatment standards, access patterns, or patient demographics, explain how the findings translate to US clinical practice.

Circulation moves fast by top-journal standards. Here's a realistic timeline:

• Desk rejection decision: 1-2 weeks. If your paper isn't going to be reviewed, you'll know quickly.
• Peer review assignment: If you pass triage, reviewers are typically assigned within 3-5 days.
• First decision: Fewer than 21 days is the editorial target. Most papers that reach review get a decision within this window.
• Revision window: Major revisions typically get 60-90 days. Minor revisions get 30-45 days.
• Final decision after revision: Usually within 7-14 days of resubmission.
• Online publication: Accepted papers go online within 1-2 weeks of final acceptance.

This speed is a genuine competitive advantage. At EHJ, you might wait 20-30 days for a first decision. At JAMA Cardiology, timelines can stretch longer. If you're sitting on a time-sensitive clinical trial result, Circulation's fast turnaround matters.

Formatting a paper for Circulation takes real effort. The structured boxes, the specific word limits, the clinical framing requirements. Don't invest that time until you're confident the paper fits.

Read five recent Circulation papers in your area. Not the abstracts. The full papers, including the structured boxes. Ask yourself whether your study is operating at the same level of clinical impact and methodological rigor.

If the answer is genuinely yes, format carefully, write those structured boxes first, and make sure every element of your submission communicates clinical relevance. Circulation's editors are making fast decisions, and they're looking for papers that make their clinical case immediately and specifically.

If you're uncertain about fit, consider running your manuscript through a pre-submission review before committing to Circulation's formatting requirements. Identifying scope misalignment early saves weeks of wasted effort.

1. How to choose the right journal for your paper, Manusights.